0647 GMT - Bayer reported strong results for the second quarter and reiterated its full-year guidance, which should be well received by investors, analysts at J.P. Morgan say in a research note. The German agriculture and pharmaceutical conglomerate reported quarterly sales and adjusted earnings that exceeded consensus expectations, and its crop-sciences and pharma divisions--the group's biggest--both beat forecasts, the analysts say. Bayer also reiterated its annual outlook at constant currency and, given that consensus estimates currently sit below the company's guidance, analysts could raise their expectations as a result, JPM says. Bayer shares are likely to outperform Tuesday, the analysts add.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments